March 2025
Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks
Novo Nordisk, UBT251, obesity treatment, triple agonist, weight loss, GLP-1, GIP, glucagon, The United Laboratories International Holdings Limited
23andMe files for bankruptcy as CEO Anne Wojcicki steps down to become bidder
Bankruptcy, CEO, Anne, Customer
Unitys eye treatment fails to match Eylea, though analysts still see a path forward
analysts, Eylea, match Eylea, Macular edema due to diabetes mellitus
Exclusive: Roivant-backed VantAI debuts AI model Neo-1, taking the big next step after AlphaFold 3
Neo-1, Study models, molecular glues
AstraZeneca Makes Potential $10B+ China Commitment Despite Political Pressure
Investments, China, Evaluation procedure
Johnson & Johnson Announces $55 Billion Investment in U.S. Manufacturing and Innovation
This major investment demonstrates J&J’s commitment to expanding its U.S. manufacturing and innovation capabilities, with potential benefits for job creation and the domestic pharmaceutical industry. The announcement aligns with broader trends of increased U.S. manufacturing investment by large corporations in recent years.
AstraZeneca details $2.5B investment in China’s political center, funding R&D center, biotech pacts
Investments, AstraZeneca, Beijing, China, China ‘s, Collaboration
J&J advances Stelara succession scheme with FDA nod for Tremfya in Crohn’s disease
Tremfya, United States Food and Drug Administration, Crohn ‘s disease, Approved, CD, J&J ‘s
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Fabhalta, United States Food and Drug Administration, Apellis, Novartis, Approved, C3 G, Proteinuria, pegcetacoplan, Kidney Diseases
Alnylam’s Amvuttra Approved for ATTR Cardiomyopathy, Challenging Pfizer and BridgeBio
Amvuttra, vutrisiran, ATTR-CM, FDA approval, RNAi therapeutic, cardiomyopathy